Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:54pm CEST

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; [email protected] 

Stocks mentioned in the article : Gilead Sciences, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 0.50% 68.17 Delayed Quote.-5.60%
ROCHE HOLDING LTD. -2.08% 219.25 Delayed Quote.-8.90%
ROCHE HOLDING LTD. -1.75% 188.38 Delayed Quote.-9.08%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
05/23GILEAD SCIENCES : to Present at the Jefferies 2018 Healthcare Conference on Wedn..
BU
05/22GILEAD SCIENCES : opens new quality control lab in Cork
AQ
05/22GILEAD SCIENCES : invest 9.5m in Cork plant to boost global drug production
AQ
05/22GILEAD SCIENCES : Gileads Kite adds cell therapy manufacturing capacity
AQ
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/17GILEAD SCIENCES : Data on Antiretrovirals Reported by Researchers at Gilead Scie..
AQ
05/17GILEAD SCIENCES : Trademark Application for "COMPASS INITIATIVE" Filed by Gilead..
AQ
05/17GILEAD SCIENCES : to Present at the Bank of America Merrill Lynch Healthcare Con..
AQ
05/17GILEAD SCIENCES : New HIV/AIDS Findings Reported from Gilead Sciences (Antiviral..
AQ
05/17FDA names, shames anticompetitive drug companies
AQ
More news
News from SeekingAlpha
05/23High Rates And Inflation Could Pose A Systemic Risk To Biotech 
05/23Is Celgene's Stock A Buy The Dip Opportunity? 
05/22CORE BIOTECH BUYS #16 : Taking Advantage Of Weakness To Add To Conviction Ideas 
05/21Should The FDA Be Shaming Drug Companies? Financial Advisors' Daily Digest 
05/21CELLECTIS : Will Focus On Universal CAR-T Payoff? 
Financials ($)
Sales 2018 20 800 M
EBIT 2018 10 683 M
Net income 2018 6 408 M
Debt 2018 13 028 M
Yield 2018 3,34%
P/E ratio 2018 13,99
P/E ratio 2019 12,56
EV / Sales 2018 4,89x
EV / Sales 2019 4,97x
Capitalization 88 639 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 85,8 $
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Andrew Cheng Chief Medical Officer & Executive Vice President
John G. McHutchison CSO, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES-5.60%88 639
VERTEX PHARMACEUTICALS4.24%39 825
REGENERON PHARMACEUTICALS-19.72%31 221
GENMAB19.78%11 932
BEIGENE LTD (ADR)97.99%10 364
BLUEBIRD BIO INC1.77%9 305